St. John's Institute of Dermatology, School of Basic and Medical Biosciences, Guy's Hospital, King's College London, London, UK.
St. John's Institute of Dermatology, School of Basic and Medical Biosciences, Guy's Hospital, King's College London, London, UK; School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK.
Trends Mol Med. 2020 Jun;26(6):615-626. doi: 10.1016/j.molmed.2020.03.002. Epub 2020 Apr 7.
Currently, IgG is the only class of antibodies employed for cancer therapy. However, harnessing the unique biological properties of a different class ( e.g., IgE) could engender potent effector cell activation, and unleash previously untapped immune mechanisms against cancer. IgE antibodies are best known for pathogenic roles in allergic diseases and for protective effector functions against parasitic infestation, often mediated by IgE Fc receptor-expressing macrophages. Notably, IgE possess a very high affinity for cognate Fc receptors expressed by tumor-associated macrophages (TAMs). This paper reviews pre-clinical studies, which indicate control of cancer growth by tumor antigen-specific IgE that recruit and re-educate TAMs towards activated profiles. The clinical development harnessing the antitumor potential of recombinant IgE antibodies in cancer patients is also discussed.
目前，IgG 是唯一用于癌症治疗的抗体类别。然而，利用不同类别（例如 IgE）的独特生物学特性可以引发有效的效应细胞激活，并释放以前针对癌症的未开发的免疫机制。IgE 抗体在过敏疾病中的致病作用以及在寄生虫感染中的保护性效应功能最为人所知，通常由表达 IgE Fc 受体的巨噬细胞介导。值得注意的是，IgE 对肿瘤相关巨噬细胞 (TAMs) 表达的同源 Fc 受体具有非常高的亲和力。本文综述了临床前研究，这些研究表明，肿瘤抗原特异性 IgE 可以控制肿瘤生长，该抗体可以招募并重新教育 TAMs，使其向激活状态转变。本文还讨论了利用重组 IgE 抗体在癌症患者中的抗肿瘤潜力的临床开发。
